Stocktwits on MSN
Capricor or Sarepta: Two DMD stocks enter a high-stakes week – which one has more upside?
Capricor is preparing a February submission to the FDA for its DMD cell therapy Deramiocel, following a formal request for the full Phase 3 Hope-3 clinical study report. ・Koyfin expects Sarepta to ...
Citi's 2026 Virtual Oncology Leadership Summit February 19, 2026 2:30 PM ESTCompany ParticipantsRafael Amado - President and Head ...
Compass will now seek approval for COMP360 in TRD, which could become the first classic psychedelic to gain the FDA’s ...
Stock market movers: futures dip in a holiday week as ZIM soars on a $4.2B buyout, biotechs rally on Phase 3 data, and WPM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results